1.A simple treatment option for Achilles tendinopathy?
Chinese Journal of Traumatology 2018;21(3):186-186
2.The Evolution of Bowel Preparation and New Developments.
Jeong Bae PARK ; Yong Kook LEE ; Chang Heon YANG
The Korean Journal of Gastroenterology 2014;63(5):268-275
Bowel preparation is essential for successful colonoscopy examination, and the most important factor is the bowel preparation agent used. However, selection of a bowel preparation agent invariably involves compromise. Originally, bowel preparation was performed for radiologic and surgical purposes, when the process involved dietary limitations, cathartics, and enemas, which had many side effects. Development of polyethylene glycol (PEG) solution led to substantive advancement of bowel preparation; however, despite its effectiveness and safety, the large volume involved, and its salty taste and unpleasant odor reduce compliance. Accordingly, modified PEG solutions requiring consumption of lower volumes and sulfate-free solutions were developed. Aqueous sodium phosphate is more effective and better tolerated than PEG solutions; however, fatal complications have occurred due to water and electrolyte shifts. Therefore, aqueous sodium phosphate was withdrawn by the US Food and Drug Administration, and currently, only sodium phosphate tablets remain available. In addition, oral sulfate solution and sodium picosulfate/magnesium citrate are also available, and various studies have reported on adjunctive preparations, such as hyperosmolar or stimulant laxatives, antiemetics, and prokinetics, which are now in various stages of development.
Administration, Oral
;
Cathartics/*administration & dosage
;
Citrates/administration & dosage
;
Citric Acid/administration & dosage
;
Colonic Diseases/diagnosis
;
Colonoscopy
;
Humans
;
Organometallic Compounds/administration & dosage
;
Phosphates/administration & dosage
;
Picolines/administration & dosage
;
Polyethylene Glycols/administration & dosage
3.A Comparison of Low-Dose and Normal-Dose Gadobutrol in MR Renography and Renal Angiography.
Ilkay Koray BAYRAK ; Zafer OZMEN ; Mehmet Selim NURAL ; Murat DANACI ; Baris DIREN
Korean Journal of Radiology 2008;9(3):250-257
OBJECTIVE: It has been advocated that a reduced injection volume with highly concentrated (1 M) contrast material can produce a sharper bolus peak and an increased intravascular first-pass gadolinium concentration when compared with the use of a lower concentration (0.5 M). A higher concentration would also cause a reduction in dose. The purpose of our study was to test the use of a low dose (0.05 mmol/kg) of gadobutrol in magnetic resonance renography and angiography and compare the findings with a dose of 0.1 mmol/kg. MATERIALS AND METHODS: One-hundred-thirty-four patients referred for magnetic resonance angiography for suspected renovascular disease participated in the study. Contrast enhanced MR renography and angiography were performed after administration of a bolus of 0.1 mmol/kg or 0.05 mmol/kg gadobutrol in randomized patients. The relative signal intensity-time curves of the aorta, peripheral cortex and parenchyma, were obtained. Two radiologists evaluated the angiographic images and evaluated the quality of angiography. RESULTS: The signal intensity with a low dose of gadobutrol was significantly lower in early phases, in the peripheral cortex (for 36, 54, 72 and 90 seconds), the parenchyma (for 36, 54, 72 seconds) and the aorta (for 18, 36, 54, 72 seconds). The decreases in the early phase obtained with a low dose of gadobutrol caused blunter time intensity curves. The difference in the quality scores of the readers for the angiographic images for the use of the two different doses was not statistically significant (p > 0.05). CONCLUSION: A lower dose of gadobutrol can be used for MR renal angiography, but for MR renography the normal dose should be used.
Contrast Media/*administration & dosage
;
Female
;
Humans
;
Hypertension, Renovascular/*diagnosis
;
Magnetic Resonance Angiography/*methods
;
Magnetic Resonance Imaging/*methods
;
Male
;
Middle Aged
;
Organometallic Compounds/*administration & dosage
4.Cutaneous Leishmaniasis of the Lid: A Report of Nine Cases.
Reza YAGHOOBI ; Sharif MARAGHI ; Nooshin BAGHERANI ; Abdolla RAFIEI
Korean Journal of Ophthalmology 2010;24(1):40-43
Leishmaniasis is a parasitic disease caused by Leishmania species and is classified into three forms; cutaneous, mucocutaneous, and visceral. The eyelid is a rare site involved by leishmaniasis and only makes up 2.5% of cases with cutaneous leishmaniasis (CL). Although CL can affect both upper and lower lids on either their outer or inner aspects, the lateral canthus is most often affected. The most common aspect of lid leishmaniasis is chalazion-like lesions but ulcerous, phagedenic, cancer-like forms, and unilateral chronic granulomatous blepharitis may be observed. When the lid is involved, the disease is usually self-limiting; healing usually takes up to one year, hence early diagnosis and treatment are important. The diagnosis is based on a high index of suspicion regarding the endemicity of the disease in the region. Response to treatment in lid CL cases is quite satisfactory. In this article, we report nine cases of lid leishmaniasis with satisfactory responses to intralesional meglumine antimoniate.
Adolescent
;
Adult
;
Child
;
Eyelid Diseases/*parasitology
;
Eyelids/*parasitology
;
Female
;
Humans
;
Infant
;
Injections, Intralesional
;
Leishmaniasis, Cutaneous/*drug therapy
;
Male
;
Meglumine/*administration & dosage
;
Organometallic Compounds/*administration & dosage
;
Treatment Outcome
5.MR Diagnosis of a Pulmonary Embolism: Comparison of P792 and Gd-DOTA for First-Pass Perfusion MRI and Contrast-Enhanced 3D MRA in a Rabbit Model.
Shella D KEILHOLZ ; Ugur BOZLAR ; Naomi FUJIWARA ; Jaime F MATA ; Stuart S BERR ; Claire COROT ; Klaus D HAGSPIEL
Korean Journal of Radiology 2009;10(5):447-454
OBJECTIVE: To compare P792 (gadomelitol, a rapid clearance blood pool MR contrast agent) with gadolinium-tetraazacyclododecanetetraacetic acid (Gd-DOTA), a standard extracellular agent, for their suitability to diagnose a pulmonary embolism (PE) during a first-pass perfusion MRI and 3D contrast-enhanced (CE) MR angiography (MRA). MATERIALS AND METHODS: A perfusion MRI or CE-MRA was performed in a rabbit PE model following the intravenous injection of a single dose of contrast agent. The time course of the pulmonary vascular and parenchymal enhancement was assessed by measuring the signal in the aorta, pulmonary artery, and lung parenchyma as a function of time to determine whether there is a significant difference between the techniques. CE-MRA studies were evaluated by their ability to depict the pulmonary vasculature and following defects between 3 seconds and 15 minutes after a triple dose intravenous injection of the contrast agents. RESULTS: The P792 and Gd-DOTA were equivalent in their ability to demonstrate PE as perfusion defects on first pass imaging. The signal from P792 was significantly higher in vasculature than that from Gd-DOTA between the first and the tenth minutes after injection. The results suggest that a CE-MRA PE could be reliably diagnosed up to 15 minutes after injection. CONCLUSION: P792 is superior to Gd-DOTA for the MR diagnosis of PE.
Animals
;
Contrast Media/administration & dosage
;
Heterocyclic Compounds/administration & dosage/*diagnostic use
;
Imaging, Three-Dimensional
;
Injections, Intravenous
;
Magnetic Resonance Angiography/*methods
;
Magnetic Resonance Imaging/*methods
;
Organometallic Compounds/administration & dosage/*diagnostic use
;
Pulmonary Embolism/*diagnosis
;
Rabbits
6.Early Assessment of Myocardial Contractility by Contrast-Enhanced Magnetic Resonance (ceMRI) Imaging after Revascularization in Acute Myocardial Infarction (AMI) .
Hong Euy LIM ; Hwan Seok YONG ; Sung Hee SHIN ; Jeong Cheon AHN ; Hong Seog SEO ; Dong Joo OH ; Young Moo RO ; Chang Gyu PARK
The Korean Journal of Internal Medicine 2004;19(4):213-219
BACKGROUND: Recent studies have demonstrated that the size and shape of the hyperenhanced areas on contrast-enhanced magnetic resonance imaging (ceMRI) were nearly identical to areas of irreversible injury, as defined by histochemical staining. We compared the transmural extent of infarct (TEI), as defined by ceMRI, to the initial ECG findings for acute myocardial infarction (AMI), and we also assessed functional contractility according to TEI. METHODS: 12 patients who presented with their first myocardial infarction underwent cine and ceMRI 4 weeks later after their successful revascularization. TEI and wall thickening were determined by using a 30-segment model. RESULTS: Infarction was observed in 81 (23.9%) segments, of which 46 segments (56.8%) had abnormal wall motion and 35 segments (43.2%) had normal wall motion. Of the 35 segments, 33 (94.3%) had subendocardial infarction. 17 segments had infarct of less than 25% of the wall thickness, and all of them had normal wall motion. On the other hand, 11 segments had infarct of more than 75% of wall thickness, of which 11 (100%) had abnormal wall motion. None of segments with nearly transmural infarction were observed in non ST-elevation AMI. The majority of the segments with infarct had non-transmural infarction (87.5%), even if the segments were in ST-elevation AMI (76.1%). Infarct size, as defined by ceMRI, was strongly correlated with peak CK-MB and Troponin-T (r=0.96, p< 0.001, r=0.91, p< 0.001, respectively). CONCLUSION: TEI defined by ceMRI is inversely related to the contractility after revascularization in AMI. We were able to predict the future contractile function of segments with infarction using ceMRI before revascularization.
Contrast Media/administration & dosage
;
Female
;
Heterocyclic Compounds/administration & dosage
;
Humans
;
Magnetic Resonance Imaging, Cine/*methods
;
Male
;
Middle Aged
;
*Myocardial Contraction
;
Myocardial Infarction/pathology/*therapy
;
*Myocardial Revascularization
;
Myocardium/*pathology
;
Necrosis
;
Organometallic Compounds/administration & dosage
7.Optimization of the Contrast Mixture Ratio for Simultaneous Direct MR and CT Arthrography: an in Vitro Study.
Ja Young CHOI ; Heung Sik KANG ; Sung Hwan HONG ; Joon Woo LEE ; Na Ra KIM ; Woo Sun JUN ; Sung Gyu MOON ; Jung Ah CHOI
Korean Journal of Radiology 2008;9(6):520-525
OBJECTIVE: This study was designed to determine the optimal mixture ratio of gadolinium and iodinated contrast agent for simultaneous direct MR arthrography and CT arthrography. MATERIALS AND METHODS: An in vitro study was performed utilizing mixtures of gadolinium at six different concentrations (0.625, 1.25, 2.5, 5.0, 10 and 20 mmol/L) and iodinated contrast agent at seven different concentrations (0, 12.5, 25, 37.5, 50, 75 and 92-99.9%). These mixtures were placed in tissue culture plates, and were then imaged with CT and MR (with T1-weighted sequences, proton-density sequences and T2-weighted sequences). CT numbers and signal intensities were measured. Pearson's correlation coefficients were used to assess the correlations between the gadolinium/iodinated contrast agent mixtures and the CT numbers/MR signal intensities. Scatter diagrams were plotted for all gadolinium/iodinated contrast agent combinations and two radiologists in consensus identified the mixtures that yielded the optimal CT numbers and MR signal intensities. RESULTS: The CT numbers showed significant correlation with iodinated contrast concentrations (r = 0.976, p < 0.001), whereas the signal intensities as measured on MR images showed a significant correlation with both gadolinium and iodinated contrast agent concentrations (r = -484 to -0.719, p < 0.001). A review of the CT and MR images, graphs, and scatter diagram of 42 combinations of the contrast agent showed that a concentration of 1.25 mmol/L gadolinium and 25% iodinated contrast agent was the best combination for simultaneous CT and MR imaging. CONCLUSION: A mixture of 1.25 mmol/L gadolinium and 25% iodinated contrast agent was found to be optimal for simultaneous direct MR arthrography and CT arthrography.
*Arthrography
;
Contrast Media/*administration & dosage
;
Gadolinium/administration & dosage/*diagnostic use
;
Iohexol/administration & dosage/*analogs & derivatives/diagnostic use
;
*Magnetic Resonance Imaging
;
Meglumine/administration & dosage/*diagnostic use
;
Organometallic Compounds/administration & dosage/*diagnostic use
;
Phantoms, Imaging
;
*Tomography, X-Ray Computed
8.Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model.
Hee Sun PARK ; Joon Koo HAN ; Jeong Min LEE ; Young Il KIM ; Sungmin WOO ; Jung Hwan YOON ; Jin Young CHOI ; Byung Ihn CHOI
Korean Journal of Radiology 2015;16(5):1029-1037
OBJECTIVE: To evaluate the utility of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using macromolecular contrast agent (P792) for assessment of vascular disrupting drug effect in rabbit VX2 liver tumor models. MATERIALS AND METHODS: This study was approved by our Institutional Animal Care and Use Committee. DCE-MRI was performed with 3-T scanner in 13 VX2 liver tumor-bearing rabbits, before, 4 hours after, and 24 hours after administration of vascular disrupting agent (VDA), using gadomelitol (P792, n = 7) or low molecular weight contrast agent (gadoterate meglumine [Gd-DOTA], n = 6). P792 was injected at a of dose 0.05 mmol/kg, while that of Gd-DOTA was 0.2 mmol/kg. DCE-MRI parameters including volume transfer coefficient (K(trans)) and initial area under the gadolinium concentration-time curve until 60 seconds (iAUC) of tumors were compared between the 2 groups at each time point. DCE-MRI parameters were correlated with tumor histopathology. Reproducibility in measurement of DCE-MRI parameters and image quality of source MR were compared between groups. RESULTS: P792 group showed a more prominent decrease in K(trans) and iAUC at 4 hours and 24 hours, as compared to the Gd-DOTA group. Changes in DCE-MRI parameters showed a weak correlation with histologic parameters (necrotic fraction and microvessel density) in both groups. Reproducibility of DCE-MRI parameters and overall image quality was not significantly better in the P792 group, as compared to the Gd-DOTA group. CONCLUSION: Dynamic contrast-enhanced magnetic resonance imaging using a macromolecular contrast agent shows changes of hepatic perfusion more clearly after administration of the VDA. Gadolinium was required at smaller doses than a low molecular contrast agent.
Animals
;
Antineoplastic Agents/therapeutic use
;
Benzophenones/therapeutic use
;
Disease Models, Animal
;
Heterocyclic Compounds/administration & dosage/*chemistry
;
Liver Neoplasms/drug therapy/pathology/*radiography
;
*Magnetic Resonance Imaging
;
Male
;
Organometallic Compounds/administration & dosage/*chemistry
;
Rabbits
;
Reproducibility of Results
;
Valine/analogs & derivatives/therapeutic use
9.Impact of sub-chronic aluminium-maltolate exposure on catabolism of amyloid precursor protein in rats.
Rui Feng LIANG ; Wei Qing LI ; Hong WANG ; Jun Xia WANG ; Qiao NIU
Biomedical and Environmental Sciences 2013;26(6):445-452
OBJECTIVETo investigate the impact of sub-chronic Aluminium-maltolate [Al(mal)3] exposure on the catabolism of amyloid precursor protein (APP) in rats.
METHODSForty adult male Sprague-Dawley (SD) rats were randomly divided into five groups: the control group, the maltolate group (7.56 mg/kg BW), and the Al(mal)3 groups (0.27, 0.54, and 1.08 mg/kg BW, respectively). Control rats were administered with 0.9% normal saline through intraperitoneal (i.p.) injection. Maltolate and Al(mal)3 were administered to the rats also through i.p. injections. Administration was conducted daily for two months. Rat neural behavior was examined using open field tests (OFT). And the protein expressions and their mRNAs transcription related with APP catabolism were studied using enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (RT-PCR).
RESULTSThe expressions of APP, β-site APP cleaving enzyme 1 (BACE1) and presenilin-1 (PS1) proteins and their mRNAs transcription increased gradually with the increase of Al(mal)3 doses (P<0.05). The enzyme activity of BACE1 in the 0.54 and 1.08 mg/kg Al(mal)3 groups increased significantly (P<0.05). The expression of β-amyloid protein (Aβ) 1-40 gradually decreased while the protein expression of Aβ1-42 increased gradually with the increase of Al(mal)3 doses (P<0.05).
CONCLUSIONResult from our study suggested that one of the possible mechanisms that Al(mal)3 can cause neurotoxicity is that Al(mal)3 can increase the generation of Aβ1-42 by facilitating the expressions of APP, β-, and γ-secretase.
Amyloidogenic Proteins ; genetics ; metabolism ; Animals ; Drug Administration Schedule ; Environmental Pollutants ; administration & dosage ; toxicity ; Gene Expression Regulation ; drug effects ; Male ; Organometallic Compounds ; administration & dosage ; toxicity ; Pyrones ; administration & dosage ; toxicity ; Random Allocation ; Rats ; Rats, Sprague-Dawley
10.Successful Treatment of Lupoid Cutaneous Leishmaniasis with Glucantime and Topical Trichloroacetic Acid (A Case Report).
Mohamad Ali NILFOROUSHZADEH ; Giti SADEGHIAN ; Fariba JAFFARY ; Hengameh ZIAEI ; Liela SHIRANI-BIDABAD ; Parvin MAHZONI
The Korean Journal of Parasitology 2008;46(3):175-177
Lupoid leishmaniasis is a unique form of cutaneous leishmaniasis characterized by unusual clinical features and a chronic relapsing course, mostly caused by infection with Leishmania tropica. In this clinical form, 1-2 yr after healing of the acute lesion, new papules and nodules appear at the margin of the remaining scar. Herein, we describe a case of this clinical form that was resistant to 2 courses of treatments: systemic glucantime and then a combination therapy with allopurinol and systemic glucantime. However, marked improvement was seen after a combination therapy with topical trichloroacetic acid solution (50%) and systemic glucantime, and there were no signs of recurrence after 1 yr of follow-up.
Administration, Topical
;
Adult
;
Antiprotozoal Agents/administration & dosage/*therapeutic use
;
Humans
;
Leishmaniasis, Cutaneous/*drug therapy/pathology
;
Male
;
Meglumine/*therapeutic use
;
Organometallic Compounds/*therapeutic use
;
Trichloroacetic Acid/administration & dosage/*therapeutic use